INTRODUCTION
Protein synthesis plays important roles in cancer onset and progression (Truitt and Ruggero, 2017) . The high production rate of proteins in cancer cells, driven by its dysregulated control, makes the inhibition of the eukaryotic protein synthesis an attractive target for the development of anticancer agents (Bhat et al., 2015; Pelletier and Peltz, 2007) . The ribosome is the protein-synthesizing factory inside each living cell. It is a large macromolecular complex made of rRNA and ribosomal proteins (~55 in bacteria, ~80 in eukaryotes) that is responsible for the correct translation of the information encoded in the mRNA into polypeptide chains. The ribosome is assembled in a sequential process during which ribosomal proteins are progressively recruited to the nascent pre-rRNAs and incorporated into maturing subunits. Recently it was shown that during subunit biogenesis, important sites on the ribosome, such as the decoding center and the exit tunnel, are monitored for integrity and function, sometimes on multiple events by different factors (Greber et al., 2016; Strunk et al., 2011; Wu et al., 2016) . Loss of this tight regulation might lead to defective ribosome assembly and, by consequence, premature cell death (Wu et al., 2016) . Inhibition of ribosome biogenesis is monitored by cells through activation of specific signaling cascades, including the antitumor nucleolar surveillance pathway leading to stabilization of the tumor-suppressor protein p53 (discussed in Nicolas et al., 2016) . In normal cells, p53 is constitutively degraded by Hdm2-mediated ubiquitylation. In cells undergoing ribotoxic stress, unassembled ribosomal components capture Hdm2 and titrate it away from p53. As a result, p53 is stabilized and a cell death program is activated (Donati et al., 2013; Sloan et al., 2013) .
Considering the central role of the ribosome in cell growth in the three kingdoms of life, it is not surprising that natural molecules have been selected during evolution as specific inhibitors of its function. Bacterial ribosome, for instance, has been shown to be the target of natural products synthesized by other bacteria or plants as part of self-defense mechanisms (Wilson, 2014) . The eukaryotic ribosome, more importantly, is the target of the first eukaryotic protein synthesis inhibitor, omacetaxine mepesuccinate (homoharringtonine, Synribo ® ), isolated primarily from Cephalotaxus harringtonii and approved by the Food and Drug Administration (FDA) in 2012 for the treatment of chronic myeloid leukemia (Al Ustwani et al., 2014) . Amaryllidaceae alkaloids The two alkaloids belong to the Amaryllidaceae family of compounds and display chemical similarity. The common methylenedioxy-phenanthridine skeleton present in both structures is shown in blue.
(AAs) are a wide family of bioactive natural compounds used in folk medicine since the Greek and Roman ages for various purposes, including cancer treatment. Their biological activities are not restricted to anticancer effects but include potential anticholinesterase, antimalarial, antiviral, and anti-inflammatory effects (Furst, 2016; Sener et al., 2003) . The most abundant alkaloids are galanthamine, lycorine (LYC), haemanthamine (HAE, Figure 1) and tazettine, together with the closely related isocarbostyryl narciclasine (NAR, Figure 1 ). Their isolation yields depend on the plant species, and the time and place of collection (Berkov et al., 2011; Lubbe et al., 2013) . Galanthamine is an FDAapproved drug for the treatment of Alzheimer's disease due to its reversible and competitive inhibitory effects on the acetylcholinesterase, while other AAs, such as NAR or HAE, do not affect the activity of cholinesterases (Kukhanova et al., 1983) . In contrast, NAR and HAE were originally suggested to share a common binding site on the eukaryotic ribosome and to specifically inhibit protein synthesis through their effects on peptide bond formation (Jimenez et al., 1976) . At the same time NAR was shown to repress growth of S180 ascites tumors (Jimenez et al., 1976) , revealing its potential as anticancer agent. We and others identified the crinine-type alkaloid HAE as a potential lead for anticancer drug development. Indeed, HAE exerts potent anticancer effects in vitro regardless of the sensitivity of cancer cells lines to apoptosis (Van Goietsenoven et al., 2010) . Moreover, HAE is effective against multidrug-resistant cells and is not a substrate for the permeability glycoprotein (P-gp) efflux pump (Hohmann et al., 2002) .
Although NAR is currently of great interest and is being pursued as a potential anticancer agent in several laboratories worldwide, a major drawback hampering its development is its poor water solubility (less than 100 mg/mL). From this perspective, HAE has a serious advantage as its water solubility is higher than 1 mg/mL and contains a basic nitrogen, allowing its potential administration in a salt form. A pharmacokinetic study of HAE in rats showed a rapid distribution phase of 30 min, a half-life of 70.4 min, and a major clearance through renal elimination (Hroch et al., 2016) . The high distribution volume of 13.7 L/kg suggests a high intracellular penetration, and its plasmatic concentration remains higher than 1 mM for at least 1 hr after a single 10-mg/kg administration (Hroch et al., 2016) . Because AAs, and HAE in particular, display several bioactivities, as mentioned above, the identification of the molecular target(s) and cellular pathways they inhibit, and the characterization of their mode of substrate binding are essential for the development of new AAbased drugs.
In this study, we solved the crystal structure of the alkaloid HAE in complex with the Saccharomyces cerevisiae 80S ribosome. We found that HAE binds at the A-site cleft of the peptidyl transferase center (PTC) on the large ribosomal subunit (LSU), creating unique molecular interactions with the 25S rRNA, which were not observed with related compounds such as NAR . In addition, we discovered that four AAs, and in particular HAE, have a highly specific inhibitory effect on pre-rRNA processing, leading to the activation of a p53dependent antitumoral surveillance pathway known as nucleolar stress (Pestov et al., 2001) . This provides important insights into the mechanism of repression of cancer cell growth by AAs. Importantly, the processing inhibition and nucleolar stress activation were not seen in cells treated with cycloheximide (CHX), an unrelated potent inhibitor of ribosome function. Finally, we present a structure-activity relationship (SAR) discussion correlating the anticancer effects with the binding preferences of HAE analogs on the 25S rRNA of the ribosome.
RESULTS

HAE Binds to the A-Site Cleft of the PTC of the Eukaryotic Ribosome
As previously mentioned, it has been proposed that HAE halts protein biosynthesis by inhibiting the peptide bond formation (Jimenez et al., 1976) . To validate these experimental results and gain further insights into the structural basis of inhibition, we solved the crystal structure of HAE in complex with the S. cerevisiae 80S ribosome at a maximal resolution of 3.1 Å ( Table 1) . Inspection of the unbiased electron density map (Fobs -Fcalc) ( Figure S1 ) revealed that the HAE binding site is located in the PTC on the LSU, and precisely in the pocket where the CCA end of the A-site transfer RNA (tRNA) is accommodated during the elongation phase (Figures 2A, 2B , and 3A). The difference map also revealed that only one molecule of HAE binds per ribosome, making the drug targeting highly specific. The binding pocket of HAE is very similar to that of NAR, whose structure in complex with the yeast 80S ribosome was recently solved . Nonetheless, our structural analysis highlights remarkable differences in binding modes of HAE and NAR to the conserved 25S rRNA residues of the A-site cleft of the PTC ( Figures 3A and 3B ). HAE is sandwiched between the 25S rRNA residues U2875 and C2821, where the aromatic ring fused to the methylenedioxy moiety can form p-stacking interactions with the nucleotide bases ( Figure 3A ). Moreover, a hydrogen bond (H bond) is formed between the C=O4 carbonyl moiety of U2875 and the amino group of the purine G2403, stabilizing the ''flip-up'' conformation of the uracil residue ( Figure 3A ). Furthermore, HAE mediates the formation of two additional H bonds involving the C11-hydroxyl group (see Figure 4 for position numbering), one with the sugar-backbone moiety and the other with the C=O2 carbonyl moiety of the base of residue U2873. These might further stabilize the accommodation of HAE in the cleft and favor the binding of a supplementary Mg 2+ atom, which was not detected previously (Ben-Shem et al., 2011; Garreau de Loubresse et al., 2014). A comparison of our structure with the NAR/80S complex (PDB: 4U51, Figure 3B ) reveals the structural rearrangement of the highly conserved residue U2875 on the 25S rRNA upon binding of HAE. Despite their related chemical structure ( Figure 1 ), binding of NAR does not induce the ''flip-up'' conformation of U2875. It is likely that the phenolic hydroxyl present in NAR, but not in HAE, is engaged in H bonding with surrounding water molecules, which would lead to the loss of hydration energy upon forming a p-stacking interaction with U2875 ( Figure 3B ). A very similar reorganization of the 25S rRNA A-site cleft is also observed when we compared our structure with the yeast vacant 80S ribosome (PDB: 4V88, Figure S2A ). In this case we additionally observed displacement of 25S rRNA residues C2821 and U2822, which accommodate HAE, similarly to what has been reported for the NAR/80S complex.
To expand our interpretation to ribosomes of higher eukaryotes, we performed structural superposition of the S. cerevisiae 25S rRNA (HAE/80S complex) with the 28S rRNA of the human 80S ribosome (PDB: 4UG0) ( Figure 3C ). The conserved residues forming the A-site cleft adopt a similar conformation, in which U4452 (U2875 in yeast) is found in an intermediate position between the vacant and HAE-bound yeast 80S ribosome (Figure 3C ), suggesting that HAE is likely to bind human ribosome similarly.
Furthermore, using the obtained structure, we aimed to understand the reason why HAE is not effective against bacteria, although prokaryotic and eukaryotic ribosomes share a common functional core (Melnikov et al., 2012) . In bacteria, U2822 is replaced by A2453, which could prevent the displacement seen in the HAE/80S structure compared with the vacant yeast 80S ribosome ( Figure S2A ). This mutation would not allow the conserved rRNA residue U2504 (U2873 in yeast) to adopt a conformation similar to that in the yeast ribosome. As a consequence, U2504 would clearly sterically clash with HAE, impeding its binding to bacterial ribosome ( Figure S3A ).
The Structure of HAE in Complex with the Eukaryotic 80S Ribosome Provides Rationalization of the Available Structure-Activity Relationships The structure of HAE in complex with the eukaryotic 80S ribosome paves the way for the understanding of the SAR data vis-a`-vis the anticancer activity of this and other crinine alkaloids. A comparative analysis of the antiproliferative activities of 56 crinine-type AAs related to HAE identified the relevant specific structural elements important for activity (Nair et al., 2012) . These are represented with well-studied natural or synthetic molecules depicted in Figure 4 . Examination of HAE and bulbispermine within the HAE binding pocket on the ribosome shows that the change in stereochemistry at C11 (as in bulbispermine Luchetti et al., 2012) or C3 (as in crinamine Likhitwitayawuid et al., 1993) , would have very little impact: these functional groups protrude into a wide opening of the pocket, which can easily accommodate either stereochemistry ( Figure 5A ). A close HAE congener, haemanthidine (HAD), bearing a C6-hydroxyl, is virtually equipotent against all cancer cells studied (Hohmann et al., 2002; Van Goietsenoven et al., 2010) . The C6-hydroxyl is not only well accommodated within the pocket, but may indeed be involved in additional hydrogen bonding to U2869 ( Figure 5B ). The derivatization of either of these alkaloids by acylating the C11-hydroxyl eradicates the activity regardless of the type of the acyl group (Cedron et al., 2015) . Examination of acylated HAE in complex with the eukaryotic 80S ribosome reveals that there is no room in the binding pocket for derivatization of the C11-hydroxyl ( Figure 5C ). Lastly, the C11,C12-ethano bridge can be positioned a or b with respect to the tricyclic skeleton, and all b-ethano-bridge-containing alkaloids are virtually inactive as shown for bufanisine ( Figure 4) (Likhitwitayawuid et al., 1993; Nair et al., 2012) . These structures cannot adopt a conformation that is compatible with the binding pocket due to a serious steric clash with U2873 ( Figure 5D ). It should be noted that the active HAE congeners in Figure 4 , i.e., haemanthidine, bulbispermine, and crinamine, retain the biological mechanism of action of HAE in that their antiproliferative action might result from the likely consequence of binding to the PTC A-site cleft as demonstrated here with HAE. Inhibition of protein synthesis was directly shown to be induced by crinamine (Novac et al., 2004) , while haemanthidine (Nair et al., 2012) and bulbispermine (Luchetti et al., 2012) elicited cancer cell phenotypes similar to that of HAE, suggesting a common mechanism of action.
Effects of AAs on Ribosome Biogenesis
Pre-rRNA processing is an excellent proxy of ribosomal assembly, because failure to assemble r-proteins in a timely fashion during subunit biogenesis usually leads to inhibition of RNA cleavage (discussed in Wu et al., 2016) . Three out of four human rRNAs are produced from a single polycistronic precursor synthesized by RNA polymerase I, the 47S pre-rRNA, by extensive processing (see Figures S4A and S4B ). In untreated cells, the 47S is rapidly processed (at sites 01, 02, A0, and 1, see Figure S4A) , so it is detected only at low levels ( Figure 6A , 0-hr time point). Inhibition of early processing reactions leads to 47S accumulation. Typically, this is seen after treatment of cells with the anticancer agent 5-fluorouracil (5-FU), a nucleotide analog that inhibits rRNA synthesis and the downstream processing steps leading to ribosome biogenesis inhibition and translational remodeling ( Figure 6A , and see Nicolas et al., 2016; Strunk et al., 2011) . We were intrigued to test whether AAs have a direct effect on pre-rRNA processing, since the PTC is assembled in the early steps of the process.
We performed total RNA extraction from cells treated with a selection of compounds in a time-course analysis and identified the major pre-rRNA intermediates ( Figures 6A and S4C ). We chose to treat cells separately with each of four AAs that bind to the A-site cleft: LYC, HAE, HAD, and NAR. For comparison, we treated cells with CHX, an E-site binder. All compounds were used in the range of their half-maximal inhibitory concentration (IC50) (Ingrassia et al., 2008; Lamoral-Theys et al., 2009; Myasnikov et al., 2016; Nita et al., 1998; Pettit et al., 2004; Van Goietsenoven et al., 2010) . We observed different effects on early processing (47S accumulation readout). CHX treatment did not seem to affect early processing considerably (no significant 47S accumulation), but all four AAs tested did so to some extent (47S accumulation). The strongest effects were observed after HAE or HAD treatments ( Figure 6A, see quantification) . In more detail, pre-rRNA processing analysis revealed further differences in processing inhibition according to the type of compound used ( Figure S4C) . 5-FU treatment affected primarily the early steps of processing (cleavages at sites 01, 02, A0, and 1, as seen by the accumulation of the 47S, 34S, 30S, and 26S RNAs). It also affected, to a lesser extent, processing in the internal transcribed spacers 1 (ITS1, reduction of 21S/21S-C) and 2 (ITS2, reduction of 32S and 12S) ( Figure S4C ). Treatment with CHX affected only cleavage at site 2 in ITS1 (30S and 21S reduction), and the effect was marginal. In addition to strongly affecting the early processing steps of the primary transcript (47S accumulation), all four AAs tested specifically inhibited large ribosomal subunit formation. Processing in ITS2, which separates the coding sequences of the 5.8S and 28S rRNAs (Figures S4A and S4B) , was particularly affected, as seen by the strong accumulation of 32S RNA (inhibition of cleavage at site 30) and 12S RNA (inhibition of maturation at site 4). In conclusion, all four AAs tested exert similar and highly specific inhibitions on pre-rRNA processing which, strikingly, are different to those caused by another translation inhibitor (CHX) or another compound that inhibits rRNA synthesis (5-FU). Note that wild-type yeast cells are resistant to HAE even to doses 10-fold higher than those used in human cells, and therefore pre-rRNA processing was not tested in this model organism ( Figure S6 ).
HAE and HAD Promote Substantial p53 Stabilization in Colon Carcinoma Cells
Cancer cells are particularly sensitive to a reduction in protein synthesis. This makes protein synthesis inhibitors promising cytostatic agents in cancer therapy (Truitt and Ruggero, 2017) . We reasoned that if, in addition to impairing translation, HAE and other AAs triggered a nucleolar stress response leading to p53 stabilization, it would make them more effective anticancer agents. Effects on protein synthesis, ribosome biogenesis, and p53 stabilization would all contribute to preferential killing of cancer cells. We were particularly interested in learning whether the processing phenotypes caused by cell treatment with AAs trigger nucleolar stress activation and an increase in the p53 steady-state level. This was tested in a time-course analysis by western blotting with an anti-p53 antibody (Figures 6B and  6C) . As loading controls, the blots were probed for several stable long-lived proteins: b-actin (a cytoskeleton protein), SP1 (a transcription factor), and GAPDH (a housekeeping metabolic enzyme) ( Figures 6B and S5 ). By comparison with 5-FU treatment, which causes a 4-fold increase in the steady-state level of p53, incubating cells with CHX led to a gradual decrease in the p53 level, in agreement with the expected gradual reduction in protein synthesis after CHX treatment. To some extent, a similar trend (gradual reduction) was observed after treatment with the AAs LYC and NAR. After treatment with HAE or HAD, in contrast, the level of p53 remained elevated throughout the depletion time course (see quantification, Figure 6C ). In these cases, p53 thus appears to be stabilized by nucleolar stress activation. Consistent with these results, the processing phenotypes caused by treatment with HAE or HAD are much stronger than those observed with the other two alkaloids tested (1,652% and 1,071% 47S accumulation after HAE or HAD treatment, respectively, versus only 450% and 206%, respectively, after NAR or LYC treatment) ( Figures 6A and S4C ). This suggests that a certain threshold of processing inhibition needs to be passed in order to trigger nucleolar stress activation.
Impedimetric Measurements Reveal Cancer Cell Sensitivity to AAs
To gain further insights into the effects of AAs in cancer cells, we monitored cell adhesion by real-time electric impedance measurements ( Figure 6D) . The same number of colon carcinoma cells were seeded into each well of gold-plated microtiter plates, and the impedance was measured every 10 min for up to 3 days. The different compounds were added once the cells were properly attached to the support (Figure 6D, red arrow) . Over the first 5 hr of treatment, addition of 5-FU, CHX, or vehicle alone (DMSO, mock) led to an initial mild reduction of cell adhesion (adhesion rate below 0 after 30 min), followed by gradual recovery. It took about 5 hr of CHX treatment to affect growth clearly, while 5-FU did not seem to have much effect within this time frame. Strikingly, the four AAs displayed distinct, but consistent, effects: after an initial increase, the cell adhesion rate started to decrease rapidly, reaching a below-zero level and growth inhibition after 2-3 hr of treatment, i.e., sooner than upon CHX treatment (5 hr). This observation is consistent with the idea that the AAs may kill cancer cells more effectively than drugs that inhibit only protein synthesis (CHX) or ribosome biogenesis (5-FU).
To prove that the effects on growth of compounds that trigger nucleolar stress require the presence of p53 in cells, we monitored cell proliferation by impedance measurements after treatment with 5-FU or HAE (both elicit p53 stabilization, Figures 6B and 6C) in two isogenic diploid human cancer cell lines: one expressing p53 (HCT116 p53 +/+ ) and one not expressing p53 (HCT116 p53 -/-) ( Figure S7 ). As controls, cells were treated with CHX (which does not lead to p53 stabilization, Figures 6B and 6C) or the vehicle alone (DMSO). In agreement with the nucleolar stress activation model (discussed in Nicolas et al., 2016) , cells treated with 5-FU are more rapidly and more severely affected for growth if they express p53 than if they do not ( Figure S7) . Similarly, upon HAE treatment, p53 -/cells grow better than p53 +/+ cells. The range of effects on growth upon 5-FU and HAE treatment is consistent with the extent of p53 stabilization: strong with 5-FU and moderate with HAE (see Figures 6B-6D ). By comparison, CHX similarly affects cells growth independently of their p53 status ( Figure S7 ). In conclusion, the reported p53 stabilization reflecting nucleolar stress activation and ribosome biogenesis inhibitions is physiologically impactful. 
DISCUSSION
AAs are potent anticancer drugs that target the eukaryotic ribosome by inhibiting protein synthesis (Jimenez et al., 1976; Garreau de Loubresse et al., 2014) . Here we have extended this conclusion to haemanthamine by mapping its binding site on the ribosome at atomic resolution (Figures 2 and 3) . The crystal structures of LYC and NAR, members of this family, in complex with the S. cerevisiae 80S ribosome have recently revealed that their target is the A-site cleft located at the PTC on the LSU (Garreau de . HAE, a crinine-type alkaloid, also belongs to the AA family, but has the substantial advantage of being soluble in water at higher concentration, making it a better candidate for future preclinical studies. Hence we were particularly interested in solving the crystal structure of HAE in complex with the eukaryotic 80S ribosome. Because HAE and NAR are both based on the methylenedioxy-phenanthridine scaffold, they were expected to share binding site and, indeed, we observed that HAE also binds to the A-site on the LSU. However, there was evidence from studies conducted in the 1970s that distinct members of the AAs display differential in vitro ribosome binding and differential in vitro translation inhibition (Baez and Vazquez, 1978) . While this suggested that individual members of the family may adopt specific modes of interaction with the ribosome, the rationale for these differences remained unknown for 50 years. One possibility is that the different compounds bind differently to the ribosomal A-site cleft. This is indeed what we confirmed here for HAE by our X-ray structural studies (see Figure S2B and Garreau de . Our crystal structure highlights the noticeable rearrangement of the conserved rRNA residue U2875 upon binding of HAE to the 80S ribosome. We observed a ~75 0 displacement of the base toward the inhibitor (''flip-up'') to establish a stacking interaction with it ( Figure 3A) . Moreover, we detected the formation of an additional H bond with residue U2873, which was not detected in the case of NAR binding (Figure 3) , which could further stabilize the alkaloid in the pocket. Superposition of our structure with the 28S rRNA of the human 80S structure (PDB: 4UG0) highlights the high similarity of the A-site cleft, further validating our interpretation of the HAE binding mode ( Figure 3C ).
The first step of the elongation phase in protein translation, after the initiator tRNA has been recognized and the 80S fully assembled, is the loading of the correct aminoacylated-tRNA (aa-tRNA) in the A-site, dictated by the mRNA sequence. The crystal structure of Thermus thermophilus 70S ribosome containing aa-tRNAs in the A and P-sites revealed the interactions occurring at the PTC between the 23S rRNA and the CCA-end tails of tRNAs (Voorhees et al., 2009 ). Contacts of the rRNA residues located at the PTC A-site take place mainly with the amino acid backbone, which makes the mechanism universal for all of the 20 different amino acids. The superposition of this structure onto our model led us to speculate that, in eukaryotes, the mechanism of inhibition occurs via a steric clash of the aa-tRNA with the alkaloid (tRNAs taken from PDB: 4V5D). The drug is placed at a distance of approximately 3 Å from the amino acid backbone and blocks the access of bulky or long side chains in the A-site cleft (Figure S3A ), thereby hindering peptide bond formation through rejection of the aa-tRNA. Steric clash interference is a mechanism of inhibition used by many protein synthesis inhibitors that bind to the functional sites of the mature ribosome (Garreau de Kö nst et al., 2017; McClary et al., 2017; Wilson, 2014) .
By comparison with its bacterial counterpart, the eukaryotic ribosome has become more complex during evolution (Melnikov et al., 2012) . This higher complexity is concentrated at the surface of the ribosome, with the addition of several ribosomal proteins and rRNA expansion segments, while the functional sites located at the core of the ribosome, such as the PTC, have maintained a high level of conservation both in sequence and structure (Melnikov et al., 2012) . This is also the case for the A-site Figure 5 . Molecular Docking based on the HAE/80S Structure Allowed Us to Better Understand the SAR Data (A) Representation, using a wire mesh surface, of the extent of the A-site binding pocket based on the HAE/80S crystal structure obtained in this study (HAE in dark blue). Significant interactions include p-stacking to C2821 and hydrogen bonding to U2873 (green dotted line). The superimposition of crinamine (green) onto HAE shows that the alternative stereochemistry at C3 is well accommodated within the constraints of the binding pocket. (B) HAD (orange) within the HAE binding pocket (by superimposition onto HAE) showing that the C6-hydroxyl group is not only well accommodated within the pocket but also possibly makes an additional hydrogen bonding connection to U2869. H bonds are represented as green dotted lines; p-stacking interactions are in pink. (C) Acylation of the HAE C11-hydroxyl results in significant steric clashes with C2821 and U2873. Derivatization of the C11-hydroxyl results in structures that cannot be accommodated within the binding pocket, leading to the understanding of the previous IC50 inhibition data. Steric clashes are represented as red dotted lines. (D) Bufanisine, which has the opposite stereochemistry at position 10b (Figure 4) , is inactive most likely because it cannot be accommodated in the pocket as a result of a serious steric clash with U2873 (represented as red dotted lines). cleft of the S. cerevisiae 25S rRNA when compared with E. coli 23S (PDB: 4YBB) ( Figure S3B ). Nonetheless, despite the overall similarity it has been previously shown that NAR does not bind to E. coli ribosomes (Baez and Vazquez, 1978) and its binding is unaffected by varying the concentration of [Mg 2+ ], [K + ], or the pH. Our analysis points out that the presence of a single rRNA substitution in the A-site cleft of bacteria, and precisely the replacement of a pyrimidine (U2822 in yeast) with a purine (A2453 in bacteria), is very likely to be responsible for HAE discrimination. This substitution would allow the conserved residue U2504 (U2873 in yeast) to adopt a different conformation and, ultimately, to sterically clash with HAE in the case of the prokaryotic ribosome ( Figure S3B) .
Based on the HAE/80S complex structure, and given the high structural similarity of the binding pocket between yeast and human 80S ( Figure 3C) , we can provide a thorough explanation of existing SAR data of HAE congeners, leading us to propose the mechanism by which these compounds might interact with, or be rejected from, the A-site cleft. This represents the first step toward the development of innovative crinine-based alkaloids as anticancer agents, which until now has been seriously hampered by the lack of structural information that could be used for rational design of superior analogs. We noticed, for instance, that HAD (Figures 4, 5A , and 5B) might create an additional H bond with the 25S rRNA, therefore explaining the slight increase in activity (Figure 4) . In contrast, acylation of C11 (see Figure 4 for numbering) gives rise to inactive compounds, due to the steric clash that would occur between the acyl group and the 25S rRNA residues (Figures 5C and 5D ). Our analysis also highlights the possible sites of functionalization of alkaloids, such as C3, which might generate a more potent compound due to the available volume that can accommodate different chemical groups and allow changes in stereochemistry. Another interesting site on alkaloids is C6, where the presence of an additional hydroxyl group slightly improves the potency of HAD thanks to the new interaction established with the 25S rRNA.
Compounds affecting protein synthesis globally are expected to also affect ribosome biogenesis simply because the process relies on numerous assembly factors and 80 ribosomal proteins that are translated by the ribosome in the cytoplasm. Moreover, since the PTC is composed only of rRNA (Polacek and Mankin, 2005) and since it is formed relatively early during subunit biogenesis, we reasoned that AA might also associate with subunit precursors, potentially interfering with assembly factor association and subunit biogenesis. The question we then asked was: do different classes of compounds exert specific effects on pre-rRNA processing? Our data showed that the addition of alkaloids (HAE, HAD, LYC, and NAR) to colon cancer cells stimulate the accumulation of the primary transcript 47S pre-rRNA ( Figures 6  and S4 ). Furthermore, the compounds also exert an inhibitory effect on the processing of the 32S and 12S rRNA in ITS2, involved in the production of the mature 28S and 5.8S, which are constituents of the LSU ( Figure S4 ). Importantly, these effects were not seen with CHX that also inhibits translation, hence demonstrating that AA-mediated processing inhibitions are highly specific.
An antitumor surveillance pathway has been described that provides a direct connection between failure of Figure 6 . Effects of AAs on Ribosome Biogenesis and p53 Homeostasis (A) Pre-rRNA processing analysis of the 47S precursor. Total RNA extracted from HCT116 cells treated with the indicated compound (concentration corresponding to their IC50, see STAR Methods) in a time-course analysis for up to 3 days was analyzed by northern blotting. The membrane was probed with an oligonucleotide specific to the primary transcript (47S). Other pre-rRNA intermediates were detected with specific probes (see Figure S4A ). (B) Analysis of p53 steady-state accumulation. Total protein was extracted from HCT116 cells treated with the indicated compound in a time-course analysis for up to 5 hr and analyzed by western blotting. The blots were probed with an antibody specific to p53 or b-actin (control). (C) Quantification of (B). The signal was quantified by luminescence with a ChemiDoc (Bio-Rad). Steady-state amounts of p53 are expressed as percentages of the level at time 0 hr. (D) Real-time impedance measurements. The cell index (CI) was captured with an iCELLigence device (ACEA) in real time for up to 5 hr after addition of the drugs and expressed as a cell adhesion rate (DCI/DT). Red arrow points to the time of compound addition. 5-FU, 5-fluorouracil; CHX, cycloheximide; LYC, lycorine; HAE, haemanthamine; HAD, haemanthidine; NAR, narciclasine. All compounds were used at their IC50. Data are presented as mean ± SEM. See also Figures S4-S7. ribosome biogenesis and p53-induced cell death (Golomb et al., 2014) . We were therefore intrigued to learn whether AAs are able to induce such a p53 response. Western blotting experiments revealed that p53 protein is stabilized after addition of HAE or HAD to colon carcinoma cells. While in normal cells the constitutive degradation of p53 avoids activation of programmed cell death, its stabilization after addition of ribosome biogenesis inhibitors represents an effective and promising way to commit cancer cells to death (Bywater et al., 2012; Peltonen et al., 2014) . Furthermore, we have shown here for 5-FU and HAE that the presence of p53 in cells is indeed required for the effect of nucleolar stress activation to be impactful on cell growth limitation (Figures 6  and S7 ).
In conclusion, the cytostatic effect of at least two AAs tested in this work (HAE and HAD) might not be due solely to their effect on protein synthesis (inhibition of mature, translating ribosomes, through binding to the A-site of the 60S subunit). It might additionally be the consequence of activation of nucleolar surveillance and consequent stabilization of p53, effects that we suggest are caused primarily by specific inhibition of pre-rRNA processing. Thus, by comparison with compounds that do not trigger a nucleolar stress response and p53 stabilization, HAE and HAD might prove advantageous in cancer therapy. As a clear perspective, we can envisage using the crystal structure of HAE in complex with the eukaryotic 80S ribosome for a computer-guided design of molecules that could potentially have enhanced potencies and reduced toxicities after specific fine-tuning of their binding selectivities.
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Detailed methods are provided in the online version of this paper and include the following: 
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